por
Rodgers, Mary A,
Olivo, Ana,
Harris, Barbara J,
Lark, Chris,
Luo, Xinxin,
Berg, Michael G,
Meyer, Todd V,
Mohaimani, Aurash,
Orf, Gregory S,
Goldstein, Yitz,
Fox, Amy S,
Hirschhorn, Julie,
Glen, William B,
Nolte, Frederick,
Landay, Alan,
Jennings, Cheryl,
Moy, James,
Servellita, Venice,
Chiu, Charles,
Batra, Rahul,
Snell, Luke B,
Nebbia, Gaia,
Douthwaite, Sam,
Tanuri, Amilcar,
Singh, Lavanya,
de Oliveira, Tulio,
Ahouidi, Ambroise,
Mboup, Souleymane,
Cloherty, Gavin A
Publicado 2022
“…STUDY DESIGN: : Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the
ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and
ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online
Artículo
Texto
